http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
기니픽에서 Salicylate가 변조이음향방사와 청성뇌간반응에 미치는 영향
이오영,박용호,이석호,남부현,박찬일 대한이비인후과학회 2002 대한이비인후과학회지 두경부외과학 Vol.45 No.7
Background and Objectives:Salicylates are well-known for producing reversible hearing loss and tinnitus. However, the site and mechanism of salicylate ototoxicity remain unresolved. Recent experiments sugest that reversible biochemical and/ or metabolic changes in the cochlea seem to play an important role in salicylate ototoxicity. The purpose of this study was to Materials and Method:ABRs and DPOAEs were observed after intraperitoneal injection of 500 mg/kg of sodium salicylate on 24 ears of guinea pigs. Results:Salicylate pro-duced a significant increase in the ABR threshold. Maximum changes were obtained in 4 hours, and recovered to the base-line in 24 hours after salicylate administration. The pattern of hearing loss shown by latency-intensity function was compatible with the cochlear type of hearing loss. The echo amplitude on DPOAEs at f2=2, 4, 6, 8 hours, and returned to the baseline in 24 hours after salicylate administration. The time course of the change of DP-OAEs was parallel with that of ABRs. Conclusion:These results reflect that the cochlear outer hair cells may be the main site of lesion in salicylate ototoxicity. (Korean J Otolaryngol 2002;45:646-50)
이오영 대한의사협회 2009 대한의사협회지 Vol.52 No.9
Gastrointestinal motility modulating drugs include all compounds which have pharmacological activity of modulating (stimulating or inhibiting) gastrointestinal motility. They are mainly used for the treatment of functional gastrointestinal diseases. Gastrointestinal motility modulating drugs include 5HT receptor agonists, antagonists, and antidopaminergic agents. Many new gastrointestinal motility modulating drugs are currently under investigation. The aims of this article are to review the mechanism of action, efficacy and side effects of the gastrointestinal motility modulating drugs.
Sigmoid Accommodation in Irritable Bowel Syndrome
이오영,전대원,한성희,양선영,윤병철,최호순,이항락,한동수,전용철,손주현,함준수,이민호,이동후,기춘석 대한소화관운동학회 2005 대한소화관운동학회 춘계학술대회 Vol.16 No.-
<목적> 최근 과민성 장 증후군 환자에서 S자 결장의 조절능에 대한 연구보고가 있지만 아직 연구가 미흡하며, 특히 아형에 따른 조절능의 차이는 알려져 있지 않다. 방법: 위장 증상이 없는 7명의 건강한 대조군(평균연령 36.7세, 남자 4명, 여자 3명)과 로마 II 기준에 의한 15명의 과민성 장 증후군 환자(평균연령 36.8세, 남자 8명, 여자 7명)를 대상으로 하였다. S자 결장에 풍선을 삽입하고 Barostat (G & J(R))를 이용하여 S
이오영,강대환,이동호,정일권,장재영,김진일,조진웅,유종선,이강문,김경오,최명규,이상우,이수택,김태오,신영운,설상영 대한약학회 2014 Archives of Pharmacal Research Vol.37 No.10
Misoprostol is reported to prevent non-steroidalanti-inflammatory drug (NSAID)-associated gastroduodenalcomplications. There is, however, limited informationregarding the efficacy of DA-9601 in this context. Weperformed a comparative study on the relative efficacy ofDA-9601 and misoprostol for prevention of NSAID-associatedcomplications. In this multicenter, double-blinded,active-controlled, stratified randomized, parallel group,non-inferiority trial, 520 patients who were to be treatedwith an NSAID (aceclofenac, 100 mg, twice daily) over a4-week period were randomly assigned to groups forcoincidental treatment with DA-9601 (60 mg, thrice daily)(236 patients for full analysis) or misoprostol (200 lg,thrice daily) (242 patients for full analysis). A total of 236patients received DA-9601 and 242 received misoprostol. The primary endpoint was the gastric protection rate, andsecondary endpoints were the duodenal protection rate andulcer incidence rate. Endpoints were assessed by endoscopyafter the 4-week treatment period. Drug-relatedadverse effects, including gastrointestinal (GI) symptoms,were also compared. At week 4, the gastric protection rateswith DA-9601 and misoprostol were 81.4 % (192/236) and89.3 % (216/242), respectively. The difference between thegroups was -14.2 %, indicating non-inferiority of DA-9601 to misoprostol. Adverse event rates were not differentbetween the two groups; however, the total scores for GIsymptoms before and after administration were significantlylower in the DA-9601 group than in the misoprostolgroup (-0.2 ± 2.8 vs 1.2 ± 3.2; p\0.0001). DA-9601 isas effective as misoprostol in preventing NSAID-associated gastroduodenal complications, and has a superioradverse GI effect profile.